Helicobacter pylori (H pylori) 
Introduction
Although the incidence of gastric cancer is declining, it remains the fourth most common cancer and the second leading cause of cancer-related deaths in the world (1) . Gastric carcinogenesis is a multifactorial process that involves complex interactions between host and environmental factors. H pylori is one of the most important environmental risk factor for gastric malignancies (2) . The chronic inflammation that develops in response to this organism contributes to tumor cell proliferation and metastasis, and affects survival (3, 4) .
Prostaglandins (PGs) play an important role in the growth and stimulation of the inflammation associated gastric carcinogenesis that is associated with H pylori infection (5-7). In particular, the expression of cyclooxygenase-2 (COX-2), a rate-limiting enzyme for prostaglandin biosynthesis, is induced in H pylori-associated carcinogenesis and results in the induction of the proinflammatory prostaglandin, PGE 2 (8, 9) . PGE 2 levels are regulated not only by its synthesis, but also by its degradation (8) . The key enzyme responsible for the biological inactivation of prostaglandins is NAD + -dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) (10) . 15-PGDH inactivates PGE 2 by catalyzing the oxidation of its 15(S)-hydroxyl group, which results in the formation of inactive 15-keto metabolites (10, 11) . Therefore, 15-PGDH plays an important role in regulating the local concentration of PGE 2 . Studies by our group and others have demonstrated that while 15-PGDH is highly expressed by normal colonic epithelial cells, transcription of 15-PGDH mRNA is lost in most colon cancers (11, 12) . Follow-up research showed that 15-PGDH may have a potential tumor suppressor function in lung, breast, bladder, thyroid, pancreas (13) (14) (15) (16) (17) and gastric cancers (18, 19) . Previously, we have demonstrated that 15-PGDH expression was lost in 70.1% of malignant human gastric tissues and 83.3% of adenomas, but was preserved in normal and metaplastic gastritis (19) . In addition, we found that the repression of 15-PGDH in gastric cancer may be due to the activation of the EGFR-ERK1/2 pathway (19) . However, it is not known whether 15-PGDH plays any role in H pylori associated gastric carcinogenesis. We hypothesized that H. pylori infection may suppress 15-PGDH expression, thereby elevating PGE 2 levels, which in turn promote gastric carcinogenesis.
Toll-like receptors (TLRs) are surface exposed pattern recognition receptors. The binding of a microbial antigen to the TLR-receptors activates their interaction with MyD88 (myeloid differentiation primary response protein-88) (20) , which triggers intracellular signals that induce the expression of inflammatory cytokines, including NF-κB; this in turn augments antiapoptotic proteins and thereby promotes the invasion and metastasis of cancer (21) . In addition, TLR4/MyD88 activation by H pylori may promote stromal macrophage activation that induces the COX2/PGE 2 pathway (22) . Accordingly, it is also possible that the TLR4/MyD88
Cancer Research. pathway mediates the suppression of 15-PGDH in H pylori infection-associated gastric carcinogenesis that elevates PGE 2 levels. The present study revealed that H pylori infection suppresses 15-PGDH transcription, which suggests that the infection decreases the degradation of PGE 2 , the major procarcinogenic prostaglandin, which in turn promotes gastric carcinogenesis. The suppression of 15-PGDH was mediated by the activation of TLR4/MyD88 and Snail transcriptional regulation by ERK1/2 and EGFR. In addition, H pylori-infected gastric specimens exhibited more 15-PGDH DNA promoter methylation than negative specimens, which suggests that epigenetic modulation contributes to the suppression of 15-PGDH transcription. Finally, 15-PGDH expression was restored after H pylori eradication, which suggests that the inhibition of 15-PGDH transcription is a reversible process.
These results indicate that the elevated PGE 2 levels in H pylori-associated gastric carcinogenesis are likely to be the consequence of both reduced catabolism and increased synthesis.
Materials and Methods

Study population
The study population consisted of 40 participants who underwent upper gastrointestinal endoscopy at Asan Medical Center between June 2011 and November 2011. Their median age was 56 years (range, 21-79 years) and 26 participants were male (65.0%). The exclusion criteria were as follows 1) consumption of a nonsteroidal anti-inflammatory drug and drugs that affect gastric acid secretion, such as antacids, bismuth compounds, H 2 -receptor antagonists, and proton pump inhibitors in 6 weeks, 2) previous gastric surgery, 3) a history of H pylori infection or eradication therapy, and/or 4) a known allergy to antibiotics. Of the 40 participants, 32 lacked symptoms and underwent an endoscopy for a routine check-up, while the remaining eight had gastrointestinal symptoms including dyspepsia, acid regurgitation, or epigastric pain (Table 1) . Of the 25 patients who were infected with H pylori, four were treated with the standard triple H pylori eradication therapy for 7 days (proton pump inhibitor 40 mg twice daily, clarithromycin 0.5g twice daily and amoxicillin 1g twice daily). At least 4 weeks later, they underwent follow-up endoscopy and sample collection.
Sample collection and determination of H pylori infection
At baseline, the subjects underwent endoscopy with biopsies for histology (two samples from the Cancer Research. The cells were washed with phosphate-buffered saline (PBS) and lysed with cell lysis buffer with 1 mM PMSF. Western blot analysis was performed as described above. The primary antibodies were polyclonal anti-15-PGDH (1:5000; Novus Biologicals, CO, USA), anti-Snail 1 (1:1000; Santa Cruz, CA, USA), antiPhospho-ERK1/2, anti-ERK1, Phospho-p38, anti-p38, Phospho-JNK 1, anti-JNK (1:1000; Cell Signaling, MA, USA), anti-TLR4, anti-TLR2 and anti-MyD88 (1:1000; Abcam, MA, USA) antibodies. Appropriate horseradish-peroxidase-conjugated secondary antibodies (Cell Signaling, MA, USA) were used. Immunoblot analysis with anti-β-actin served as a loading control.
Immunohistochemistry
The H pylori-negative and -positive tissues were subjected to immunohistochemical staining for 15-PGDH by using a monoclonal anti-15-PGDH antibody (provided by Sanford D. Markowitz) (12) . The tissues were fixed in 10% formalin and embedded in praffin. Four-micrometer-thick sections were deparaffinized with xylene and then gradually rehydrated with a graded series of alcohol solutions. 15-PGDH staining was performed as described previously (19) . In short, Antigen retrieval was performed (60 min at 96°C) in 10 mM citrate buffer (pH 6.0). The primary anti-15-PGDH (1:5000 dilution) antibody was incubated overnight at 4°C.
The slides were incubated with Dako Envision System Kit (DAKO, Glostrup, Denmark) and developed with DAB solution (Dako, Glostrup, Denmark). Finally, the sections were counterstained with hematoxylin. All slides were reviewed by one gastrointestinal pathologist.
Bisulfite modification and methylation-specific PCR (MSP)
Genomic DNA was isolated from gastric tissues by using a DNeasy tissue extraction kit (Qiagen, Maryland, USA) and then subjected to bisulfate modification with an EZ DNA Methylation-Gold kit (Zymo Research, CA, USA). The modified DNA was amplified with primers that were specific for either the were separated on a 2% agarose gel and detected by ethidium bromide staining.
Pyrosequencing analysis
Each primer was designed by using the PSQ assay design program (Biotage, Uppsala, Sweden). The primer sequences that were used are listed in supplementary Table S1 . The amplification was carried out initiated at 95 for 10 min, followed by 45 cycles at 95 for 30 sec, at 55 for 30 sec, at 72 for 30 sec and final extension at 72 for 5 min. The single-stranded DNA template was prepared from biotinylated PCR product by using streptavidin Sepharose ® HP beads (Amersham Biosciences, Sweden) as described by the PSQ 96 sample preparation guide. Sequencing was performed on a PyroMark ID system by using the PyroGold reagents kit (Biotage, Uppsala, Sweden) according to the manufacturer's instructions. The percentage of 15-PGDH methylation was determined by calculating the average methylation at 10 CpG sites in pyrosequencing.
Cell culture and H pylori infection
The treatments, the AGS cells were cultured for 24 hrs and subsequently treated with LPS (1 μg/ml or 10 μg /ml; Sigma, MO, USA) for 12 hr.
Small interfering RNA
Small interfering RNA (siRNA) for Snail 1 (UUGCAGUUGAAGGCCUUUCGUU), MyD88 (GCUCAUCGAAAAGAGGUGC) (23) and negative control siRNA were purchased from Genolution (Seoul, Korea) and Invitrogen (CA, USA), repectively. The AGS cells were cultured in 60mm cell culture dish for 24 hrs at 37 ºC. Before H.pylori infection, The cells were transfected for 48hrs with 50 nmol/L siRNA by using Lipofectamine™ RNAiMAX (Invitrogen Inc., CA, USA) as described by the manufacturer's instructions. The medium was replaced and the cells were infected with H.pylori.
Statistics
Statistical analysis was performed by using GraphPad PRISM version 5.01 for Window (GraphPad Software, San Diego, USA). Differences between two groups in terms of continuous variables were analyzed by using the Student's t test and Mann-Whitney test, while differences in terms of categorical variables were evaluated by using the X 2 test or Fisher's exact test. P values of <0.05 were considered to indicate statistically significant differences. 
Results
Clinical characteristics of the study population
15-PGDH expression is down-regulated in H pylori-positive specimens
To investigate the regulation of 15-PGDH expression in the infected gastric specimens, the H pyloripositive and -negative gastric specimens taken at baseline were first compared in terms of 15-PGDH mRNA expression. As shown in Fig. 1A , the positive specimens had significantly lower 15-PGDH mRNA expression than the negative specimens (P= 0.0004) but did not differ in terms of COX-2 mRNA expression (P=0.6395) (Fig. 1E) .
15-PGDH down-regulation and Snail up-regulation in H pylori-infected AGS cells and their role in regulation of TLR4-ERK pathway
To investigate the mechanism underlying the H pylori associated suppression of 15-PGDH expression, AGS cells (which has a high endogenous level of 15-PGDH) were infected with H pylori (Supplementary Fig.   S1A ). Western blot analysis revealed that the H pylori infection significantly decreased 15-PGDH protein levels ( Fig. 2A, Supplementary Fig. S1B ) and increased the transcription factor, Snail, after 4hrs ( Fig. 2A) . To determine whether inhibition of 15-PGDH was specific for the H pylori, we examined whether 15-PGDH expression was affected by LPS treatment. 15-PGDH expressions did not change after LPS treatment in AGS cells ( Supplementary Fig. S2 ). Since previous reports have demonstrated that the transcription factor Snail represses the transcription of 15-PGDH (24, 25) . We confirmed that inhibition of Snail using siRNA against Snail 1 blocked the H pylori-mediated down-regulation of 15-PGDH expression (Fig. 2B) 
down-regulation of 15-PGDH in H pylori-infected AGS cells. Pretreatment with PD98059, AG1478 and LY294002 partially reversed the stimulatory effect of H pylori on Snail (Fig. 2C) . However, blocking with PD98059 and AG1478, an ERK1/2 and EGFR inhibitor, restored the down-regulation of 15-PGDH mediated by H pylori infection (Fig. 2B) . To determine if ERK1/2 is activated by H pylori infection, we performed a western blot for active, phosphorylated ERK1/2 (p-ERK1/2) and found that ERK1/2 was activated by H pylori within 1hr after infection commenced, with maximal activity occurring by 2hr (Fig. 2D) . We also demonstrated that another MAPK pathway signaling p38 and JNK were activated by H pylori (Supplementary Fig. S3A ), however, only blocking with PD98059 restored 15-PGDH expressions and suppressed up-regulated Snail expressions by H pylori (Supplementary Fig. S3B ). These results indicated that activation of the ERK1/2 pathway by H pylori is specific for Snail up-regulation and subsequent 15-PGDH suppression by H pylori infection.
TLR4 regulates the response of human gastric epithelial cells to H pylori (26) . To test whether it participates in the H pylori-mediated suppression of 15-PGDH, infected AGS cells were subjected to western blot analysis of TLR4 expression. The expression MyD88 was also examined because it is an adaptor molecule that participates in TLR signaling (20) . H pylori infection significantly induced TLR4 protein expression after 5 min of exposure, while the expression of MyD88 increased between 5 min and 1 hr of exposure (Fig. 2E ). In addition, TLR2 expression was increased by H pylori infection (Supplementary Fig. S4 ).
To investigate the functional role of MyD88 in H pylori-associated 15-PGDH regulation, an siRNA against MyD88 was used to knock-down MyD88 expression. Interestingly, the inhibition of MyD88 blocked the H pylori-mediated down-regulation of 15-PGDH expression (Fig. 2F) . It also significantly suppressed the H pylori-induced phosphorylation of ERK1/2 (Fig. 2F) , which suggests that the 15-PGDH suppression was mediated by TLR4/MyD88 and activated ERK1/2.
Promotor Methylation of 15-PGDH DNA in H pylori positive Gastric tissues
To investigate the significance of 15-PGDH promoter methylation in H pylori-infected gastric specimens, the 15-PGDH promoter methylation status of 13 H pylori-negative and 20 positive specimens was examined. In 14 of the 20 H pylori-positive subjects (70%), the 15-PGDH promoter showed increased methylation (Fig. 3A) . In contrast, only five of the 13 H pylori-negative subjects (38%) showed this (Fig. 3A) .
To assess the precision with which bisulfate-PCR determined the 15-PGDH promoter methylation in gastric specimens, the 20 positive and 13 negative specimens were also subjected to pyrosequencing analysis. The percent methylation for 10 CpG sites analyzed ranged from 2.6 to 6. while only from 1.7 to 4.3 percent methylated in H pylori negative subjects. The levels of 15-PGDH promoter methylation was significantly higher in H pylori positive specimens compared with negative ones (P= 0.0111) (Fig. 3B) . When all samples were pooled and divided into two groups that had >4% and ≤4% promoter methylation, respectively, the group with >4% promoter methylation had significantly lower 15-PGDH mRNA levels than the ≤4% group (P= 0.0097) (Fig. 3C) suggesting that the subtle increase in 15-PGDH methylation seen in H pylori infected individuals in vivo may play a role in modulating 15-PGDH mRNA levels.
Restoration of 15-PGDH expression after H pylori eradication
To explore whether H pylori-associated suppression of 15-PGDH expression can change if H pylori is eradicated, gastric samples were collected from four of the H pylori-positive subjects 8 weeks after triple therapy regimen and the 15-PGDH mRNA expression was evaluated. In all four cases, 15-PGDH mRNA expression rose markedly after treatment (Fig. 4A) , while the expression of COX-2 mRNA decreased in three of the four cases (Fig. 4B) . A follow-up CLO test and histologic examination showed that all four patients had become H pylori-negative after treatment.
Discussion
Infection-associated inflammation plays an important role in promoting cancer development (27) .
Examples of cancers that are linked to infection include bladder cancer (shistosomiasis), hepatocellular carcinoma (hepatitis B and C infection), cervical cancer (human papilloma virus), and gastric cancer (H pylori infection) (27) . Such "tumor-promoting inflammation" is now considered to be one of the "hallmarks of cancer" (28) . In the pathophysiologic mechanism of inflammation associated carcinogenesis, activated prostaglandins are critical for stimulating cell invasion and promoting angiogenesis (5, 7). The present study showed for the first time that 15-PGDH (a key enzyme that degrades major prostaglandins) was down-regulated by H pylori infection in the human stomach. This suggests that H pylori infection represses the catabolism of prostaglandins, which elevates prostaglandin levels, which in turn may promote gastric carcinogenesis. The present study also showed for the first time that this process was reversible: 15-PGDH expression recovered after H pylori was induces Snail, which binds conservd E-box elements in the PGDH promoter to repress transcription (25) . We elucidated that H pylori associated signaling pathway involving TLR4-MyD88 and ERK1/2 is also related to the 15-PGDH suppression that might be related with gastric carcinogenesis. In addition, a modest elevated CpG island methylation of 15-PGDH DNA was found associated with the down-regulation of 15-PGDH by H pylori.
Recent studies including our own, have suggested that 15-PGDH behaves as a tumor suppressor in several tumor types including colon, lung, breast, bladder, thyroid and pancreas carcinomas (12) (13) (14) (15) (16) (17) . Previously, we reported that 70.1% of gastric cancer specimens lack 15-PGDH protein expression (19) . In addition, exploration of 15-PGDH expression in preneoplastic lesions showed that while 15-PGDH repression was not present in metaplasia, it was markedly reduced in 83.3% of adenomas (19) . The present study showed that, 15-PGDH was even repressed in H pylori positive specimens that only showed mild gastritis. This suggests that H pylori infection initiates gastric carcinogenesis by elevating PGE 2 levels even before the formation of preneoplastic lesion. The elevated expression of COX-2 is also found in more than 70% of gastric cancers, and this is reversed when H. pylori is eradicated (29) . In addition, transgenic mice expressing COX-2 and the PGE 2 -converting enzyme microsomal prostaglandin E synthase-1 (mPGES-1) develop hyperplastic gastric tumors, which suggests that the activation of prostaglandin synthesis plays a major role in H pylori-associated gastric carcinogenesis (30) . The present study also demonstrated that elevated PGE 2 levels in gastric carcinogenesis are a consequence of not only increased synthesis but also reduced catabolism.
Murine model studies have indicated that PGE 2 suppresses the T helper 1 immune response in the H pylori-infected stomach and that inhibition of COX-2 enzymatic activity accelerates the development of gastritis and premalignant gastric lesions; moreover, systemic administration of synthetic PGE 2 prevents premalignant changes (7). These observations suggest that PGE 2 may suppress infection-associated carcinogenesis, which appears to be inconsistent with the present results. PGE 2 also promotes crypt stem cell survival and proliferation (31) and plays a role in the wound-healing process by enhancing the production of vascular endothelial growth factor (VEGF), a key factor in angiogenesis (32) . 15-PGDH is also down-regulated in inflammatory bowel diseases (33) . Thus, in the short term, it seems likely that the reduced degradation of PGE 2 in infected gastric tissue contributes to the healing of the inflamed mucosa. However, if the elevation of PGE 2 in inflamed mucosa is chronic, it may stimulate mitogenesis and inhibit apoptosis, thereby lowering the threshold for the development of cancer. Recent reports suggest that bacterial infection, in cooperation with PGE 2 signaling through the EP4 receptor, induces macrophage recruitment and promotes gastric tumorigenesis by TNF-a and Wnt signaling (6) . This supports the notion that chronic activation of PGE 2 has procarcinogenic effects. The Cancer Research. 
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short term effect of PGE 2 activation on gastric carcinogenesis should be investigated in future studies.
The 15-PGDH gene has two regions that contain clusters of putative transcription factor-binding sites.
The transcription factors that have been reported to regulate these regions are Ets, activating protein-1 (AP-1), Snail, Alug, and ZEB1 (10) . Previous studies indicate that EGFR activation suppressed 15-PGDH through Snail (25) . In addition, blockade of EGFR signaling induces 15-PGDH while reducing Snail in vitro and PGE 2 -dependent xenografts model (25) . EGFR signaling induces Snail, which binds to conserved E-box elements in the 15-PGDH promoter to repress transcription (25) . In our study, analysis of the mechanism by which H. pylori This result is consistent with our previous report, which suggests that 15-PGDH is repressed in gastric cancer by the activation of the EGFR-ERK1/2 pathway (19).
The present study also assessed whether the TLR/MyD88 pathway, which is a well-known bacterial recognition system, plays a role in the H pylori-associated repression of 15-PGDH. It was found that TLR4 and MyD88 were activated by H pylori, as has been reported previously (20) . To elucidate whether MyD88 is needed for H pylori-induced 15-PGDH repression, a siRNA against MyD88 was used. Interestingly, this siRNA lifted the repression of 15-PGDH and blocked the phosphorylation of ERK1/2. These observations together suggest that H pylori activate TLR4/MyD88, thereby elevating ERK1/2 phosphorylation, which in turn represses 15-PGDH expression (Diagram 1).
TLR4 signaling via MyD88 activates a signaling cascade that results in the enhanced transcription of COX-2 and the increased production of PGE 2 (22, 23) . PGE 2 activates Wnt and peroxisome proliferatoractivated receptor-δ signaling to induce target genes involved in replication and survival; it also triggers cell migration by activating the EGFR pathway (5, 8) . The present study identified another pathway that could promote gastric carcinogenesis, namely one where the catalysis of PGE 2 by 15-PGDH is suppressed via TLR4/MyD88 signaling. Notably, our analysis of human samples revealed that H. pylori infection clearly down- The main strategies of gastric cancer chemoprevention include H pylori eradication and the use of non-steroidal anti-inflammatory drugs that mainly target the inhibition of prostaglandin synthesis (34) . Previous trials on drugs that inhibit COX-2 activity and that could decrease the risk of colon carcinogenesis showed that these drugs are problematic because they induce unfavorable cardiovascular side effects (35) . Our previous data indicated that these side effects can be reduced by using effective biomarkers such as 15-PGDH to select the subjects who will benefit from these chemopreventive drugs (36) . In addition, we hypothesize that gastric neoplasia could be prevented by combining H pylori eradication with compounds that can act in the gastrointestinal tract to re-induce 15-PGDH expression in early neoplastic cells.
We could not recruit enough patients because it was very difficult to get the permission for the sampling in patients before and after H pylori eradication therapy. However, we believe that our preliminary result provide valuable suggestion that 15-PGDH can be restored after H pylori eradication. Further study including long-term follow up measurement will be necessary to prove this hypothesis.
In conclusion, the present study demonstrated that 15-PGDH, a novel tumor suppressor, was significantly down-regulated in H pylori-infected gastric human tissues, which suggests that H pylori infection may repress the catabolism of prostaglandins, thereby elevating prostaglandin levels, which could promote gastric carcinogenesis. An in vitro study revealed that this process is mediated by TLR4-MyD88 activation and 
